Article Information
History
- March 31, 2022.
Article Versions
- Version 1 (March 14, 2022 - 16:15).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jonathan M Cohen1,2,*,
- Michael J Carter3,4,
- C Ronny Cheung5,6,
- Shamez Ladhani7,8,
- Evelina PIMS-TS Study Group
- 1Paediatric Immunology & Infectious Diseases, Evelina London Children’s Hospital, London, UK
- 2UCL Great Ormond Street Institute of Child Health, London, UK
- 3School of Life Course and Population Sciences, King’s College London, London, UK
- 4Paediatric Intensive Care Unit, Evelina London Children’s Hospital, London, UK
- 5General Paediatrics Department, Evelina London Children’s Hospital, London, UK
- 6Faculty of Life Sciences and Medicine, King’s College London, London, UK
- 7Immunisation Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK
- 8Paediatric Infectious Diseases Research Group (PIDRG), St. George’s University of London, Cranmer Terrace, London SW17 0RE, UK
- ↵*Corresponding Author:
Paediatric Immunology & Infectious Diseases, Evelina London Children’s Hospital, 3rd Floor Becket House, Westminster Bridge Road, London, SE1 7EH, United Kingdom., Jonathan.cohen2{at}nhs.net. Tel: +44-207-188-4679.
Posted March 31, 2022.
Lower Risk of Multisystem Inflammatory Syndrome in Children (MIS-C) with the Delta and Omicron variants of SARS-CoV-2
